vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and Iterum Therapeutics plc (ITRM). Click either name above to swap in a different company.
Solowin Holdings, Ltd. is the larger business by last-quarter revenue ($410.0K vs $390.0K, roughly 1.1× Iterum Therapeutics plc). Solowin Holdings, Ltd. produced more free cash flow last quarter ($-1.6M vs $-7.5M).
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
AXG vs ITRM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $390.0K |
| Net Profit | — | $-9.0M |
| Gross Margin | — | — |
| Operating Margin | -34.1% | -1982.3% |
| Net Margin | — | -2302.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -47.3% |
| EPS (diluted) | — | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $11.0M |
| Total DebtLower is stronger | — | $20.0M |
| Stockholders' EquityBook value | $6.0M | $-7.4M |
| Total Assets | $13.1M | $32.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $11.0M | ||
| Q3 24 | $2.5M | — |
| Q3 25 | — | $20.0M | ||
| Q3 24 | — | — |
| Q3 25 | — | $-7.4M | ||
| Q3 24 | $6.0M | — |
| Q3 25 | — | $32.5M | ||
| Q3 24 | $13.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-7.4M |
| Free Cash FlowOCF − Capex | $-1.6M | $-7.5M |
| FCF MarginFCF / Revenue | -392.9% | -1912.6% |
| Capex IntensityCapex / Revenue | 4.4% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.4M | ||
| Q3 24 | $-1.6M | — |
| Q3 25 | — | $-7.5M | ||
| Q3 24 | $-1.6M | — |
| Q3 25 | — | -1912.6% | ||
| Q3 24 | -392.9% | — |
| Q3 25 | — | 3.1% | ||
| Q3 24 | 4.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
